Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report.

IF 3.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-11-24 DOI:10.5306/wjco.v16.i11.112029

Xiao-Ting Ma, Guang-Yu Yao, Jian-Li Li, Xi-Cheng Wang, Yi Ba

{"title":"Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report.","authors":"Xiao-Ting Ma, Guang-Yu Yao, Jian-Li Li, Xi-Cheng Wang, Yi Ba","doi":"10.5306/wjco.v16.i11.112029","DOIUrl":null,"url":null,"abstract":"Background: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) represents a distinct molecular cancer subtype that is often associated with a poor prognosis. While perioperative chemotherapy regimens are currently the primary recommendation for locally advanced HER2-positive GC, combination therapies incorporating immune checkpoint inhibitors are under active investigation.Case summary: The present case describes a patient with locally advanced HER2-positive GC who underwent perioperative treatment with chemotherapy combined with trastuzumab. Although significant tumor shrinkage was observed, surgical pathology results did not confirm the achievement of a pathological complete response. The current treatment strategies for advanced GC were also reviewed. Relevant case reports, retrospective studies, and prospective clinical trials were retrieved for analysis after searching the PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, and American Society of Clinical Oncology/European Society for Medical Oncology conference abstracts between 2014 and 2024.Conclusion: Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 11","pages":"112029"},"PeriodicalIF":3.6000,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i11.112029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) represents a distinct molecular cancer subtype that is often associated with a poor prognosis. While perioperative chemotherapy regimens are currently the primary recommendation for locally advanced HER2-positive GC, combination therapies incorporating immune checkpoint inhibitors are under active investigation.

Case summary: The present case describes a patient with locally advanced HER2-positive GC who underwent perioperative treatment with chemotherapy combined with trastuzumab. Although significant tumor shrinkage was observed, surgical pathology results did not confirm the achievement of a pathological complete response. The current treatment strategies for advanced GC were also reviewed. Relevant case reports, retrospective studies, and prospective clinical trials were retrieved for analysis after searching the PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, and American Society of Clinical Oncology/European Society for Medical Oncology conference abstracts between 2014 and 2024.

Conclusion: Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.

Abstract Image

查看原文本刊更多论文

人表皮生长因子受体2阳性局部进展期胃癌围手术期免疫治疗联合标准治疗1例。

背景：人表皮生长因子受体2 （HER2）阳性胃癌（GC）是一种独特的分子癌症亚型，通常与预后不良相关。虽然围手术期化疗方案目前是局部晚期her2阳性胃癌的主要推荐方案，但结合免疫检查点抑制剂的联合治疗正在积极研究中。病例总结：本病例描述了一位局部晚期her2阳性胃癌患者，接受化疗联合曲妥珠单抗围手术期治疗。虽然观察到明显的肿瘤缩小，但手术病理结果并没有证实病理完全缓解的实现。综述了目前晚期气相色谱的治疗策略。检索PubMed/MEDLINE、EMBASE、Cochrane图书馆、Web of Science和美国临床肿瘤学会/欧洲肿瘤医学学会2014 - 2024年会议摘要，检索相关病例报告、回顾性研究和前瞻性临床试验进行分析。结论：联合新辅助治疗应用于胃癌的疗效尚需大规模III期临床试验验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.